Every Form 4 that Apogee Therapeutics Inc (APGE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow APGE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APGE filings page.
Apogee Therapeutics (APGE) reported insider activity by its Chief Medical Officer on 11/05/2025. The officer exercised 8,060 stock options at $22.86 and sold common shares in multiple open‑market transactions: 2,300 at $53.62, 2,200 at $54.83, 5,607 at $55.58, and 678 at $56.51.
Following these trades, the officer directly owned 282,008 common shares and held 153,565 derivative securities (options). The filing notes the sales were executed under a Rule 10b5‑1 trading plan adopted on August 21, 2024, with several prices reported as weighted averages across multiple executions.
Apogee Therapeutics (APGE) director Nimish Shah reported acquiring 365,853 pre-funded warrants on 10/10/2025 at $40.9999 per warrant. The warrants are immediately exercisable at $0.00001 per share and have no expiration, subject to a 4.99% beneficial ownership limit. The securities are held by Venrock Opportunities Fund; Shah reports indirect ownership and disclaims beneficial ownership beyond his indirect pecuniary interest.
Apogee Therapeutics (APGE) filed a Form 4 for its Chief Medical Officer. On 10/01/2025, the officer exercised 2,385 stock options at $22.86 and sold 5,110 shares at a weighted average price of $39.8 pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.
Following these transactions, beneficial ownership stood at 284,733 shares held directly. Derivative holdings included 161,625 stock options remaining. The option referenced represents the right to purchase 175,345 shares, vesting in forty-eight equal monthly installments through December 18, 2027.